Komori
Kringle Pharma (4884) · RiskFirst stated

Liability for damages arising from serious adverse reactions during clinical trials and after commercialization

First written in FY2022. . Latest entry: FY2022.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Health Damage and Product Liability Risks Associated with PharmaceuticalsA theme 58 companies write about · 67 as a headwind · 1 as a tailwind

The whole theme swung hardest in 2026: 6 of 20 companies on the "Worse" side.

0 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 58 companies compared. The sentences above are computed from all 58.
Full recordFilings, disclosures and news, newest first
  1. FY2022First statedAnnual report

    「Serious adverse reactions to investigational drugs may occur during clinical trials of pharmaceuticals. We have liability insurance against this risk, but may nevertheless incur an obligation to pay damages outside the scope of the insurance.」

    The company discloses the risk of liability for damages arising from serious adverse reactions during clinical trials and after approval, despite maintaining insurance coverage.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Kringle Pharma yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Liability for damages arising from serious adverse reactions during clinical trials and after commercialization | Kringle Pharma,Inc. (4884) | Komori